Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine
- PMID: 24699471
- DOI: 10.1016/j.vaccine.2014.03.063
Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine
Abstract
Background: In 2008, a diphtheria, tetanus, acellular pertussis, and inactivated poliovirus combined vaccine (DTaP-IPV) was licensed for use in children 4 through 6 years of age. While pre-licensure studies did not demonstrate significant safety concerns, the number vaccinated in these studies was not sufficient to examine the risk of uncommon but serious adverse events.
Objective: To assess the risk of serious adverse events following DTaP-IPV vaccination.
Methods: The study was conducted from January 2009 through September 2012 in the Vaccine Safety Datalink (VSD) project. In the VSD, electronic vaccination and encounter data are updated and aggregated weekly as part of ongoing surveillance activities. Based on previous reports and biologic plausibility, eight potential adverse events were monitored: meningitis/encephalitis; seizures; stroke; Guillain-Barré syndrome; Stevens-Johnson syndrome; anaphylaxis; serious allergic reactions other than anaphylaxis; and serious local reactions. Adverse event rates in DTaP-IPV recipients were compared to historical incidence rates in the VSD population prior to 2009. Sequential probability ratio testing was used to analyze the data on a weekly basis.
Results: During the study period, 201,116 children received DTaP-IPV vaccine. Ninety-seven percent of DTaP-IPV recipients also received other vaccines on the same day, typically measles-mumps-rubella and varicella vaccines. There was no statistically significant increased risk of any of the eight pre-specified adverse events among DTaP-IPV recipients when compared to historical incidence rates.
Conclusions: In this safety surveillance study of more than 200,000 DTaP-IPV vaccine recipients, there was no evidence of increased risk for any of the pre-specified adverse events monitored. Continued surveillance of DTaP-IPV vaccine safety may be warranted to monitor for rare adverse events, such as Guillain-Barré syndrome.
Keywords: Acellular pertussis; Diphtheria; Immunization; Inactivated poliovirus combined vaccine; Surveillance; Tetanus; Vaccine; Vaccine safety.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Similar articles
-
Adapting group sequential methods to observational postlicensure vaccine safety surveillance: results of a pentavalent combination DTaP-IPV-Hib vaccine safety study.Am J Epidemiol. 2013 Jan 15;177(2):131-41. doi: 10.1093/aje/kws317. Epub 2013 Jan 4. Am J Epidemiol. 2013. PMID: 23292957 Clinical Trial.
-
Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.Vaccine. 2011 Feb 11;29(8):1551-7. doi: 10.1016/j.vaccine.2010.12.094. Epub 2011 Jan 6. Vaccine. 2011. PMID: 21215828 Clinical Trial.
-
New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).Ann Pharmacother. 2010 Mar;44(3):515-23. doi: 10.1345/aph.1M468. Ann Pharmacother. 2010. PMID: 20197476 Review.
-
Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years.Expert Rev Vaccines. 2008 Nov;7(9):1309-20. doi: 10.1586/14760584.7.9.1309. Expert Rev Vaccines. 2008. PMID: 18980534 Review.
-
An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.Vaccine. 2007 Jan 22;25(6):1121-5. doi: 10.1016/j.vaccine.2006.09.053. Epub 2006 Oct 2. Vaccine. 2007. PMID: 17045366 Clinical Trial.
Cited by
-
Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data.Am J Epidemiol. 2023 Feb 1;192(2):205-216. doi: 10.1093/aje/kwac170. Am J Epidemiol. 2023. PMID: 36193854 Free PMC article.
-
Post-Marketing Surveillance of Tetravalent Diphtheria-Tetanus-Acellular Pertussis and Inactivated Poliovirus (DTaP-IPV) Vaccine in South Korea, 2009 to 2015.Infect Dis Ther. 2022 Aug;11(4):1479-1492. doi: 10.1007/s40121-022-00650-8. Epub 2022 May 14. Infect Dis Ther. 2022. PMID: 35575974 Free PMC article.
-
Current Take on Systemic Sclerosis Patients' Vaccination Recommendations.Vaccines (Basel). 2021 Dec 2;9(12):1426. doi: 10.3390/vaccines9121426. Vaccines (Basel). 2021. PMID: 34960174 Free PMC article. Review.
-
Continuous Post-Market Sequential Safety Surveillance with Minimum Events to Signal.Revstat Stat J. 2017 Jul;15(3):373-394. Revstat Stat J. 2017. PMID: 34393695 Free PMC article.
-
Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999-2017.Vaccine. 2020 Feb 11;38(7):1746-1752. doi: 10.1016/j.vaccine.2019.12.028. Epub 2019 Dec 20. Vaccine. 2020. PMID: 31870573 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical